Publications
Search our bibliography using the filters on the right-hand side.
Displaying 301 through 350 of 729 publications.
Skip to main content
Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.
Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.
Lucas A, Wilson M, Wasserman M, Jones D, Vyse A, Slack M, Hilton B, Madhava H, Farkouh R. Dynamic transmission modeling of pneumococcal conjugate vaccine and potential dosing reduction in the United Kingdom. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 17, 2018. Melbourne, Australia.
Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Wasserman M, Lucas A, Wilson M, Farkouh R, Brogan A, Hilton B, Jones D. Dynamic transmission modeling to address infant pneumococcal conjugate vaccine schedule modifications. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Graham C, McGuire M, Knox H, Ung B. Budget impact analysis of enasidenib treatment in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S31.
Krishnarajah G, Knox H, Graham CN, Christiansen S, Zuraw B. Subcutaneous C1-inhibitor prophylactic treatment for hereditary angioedema: a budget impact model. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S37.
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Buck PO, Curran D, Patterson BJ, Varghese L, Van Oorschot D, Carrico J, Hicks K, Lee BY, Yawn BP. Cost-effectiveness of adjuvanted recombinant zoster vaccine (RZV) for vaccinating US adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Zuluaga-Sanchez S, Hess LM, Wolowacz SE, D'yachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for patients with soft tissue sarcoma in the United States. Sarcoma. 2018 Mar 26;2018:6703963. doi: 10.1155/2018/6703963
Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, Van Oorschot D, Lee B, Yawn B. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and postherpetic neuralgia case avoidance in the United States for people previously vaccinated against HZ. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the American Society Health System Pharmacist (ASHP) Conference.
Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, Van Oorschot D, Lee B, Yawn B. Assessment of the potential herpes zoster and postherpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the IDWeek 2017 Conference.
Schelfhout J, Jiang Y, Miles L, Merchant S, Graham J. Cost effectiveness of letermovir as cytomegalovirus prophylaxis in in allogeneic hematopoietic stem cell transplant recipients. Poster presented at the 2018 BMT Tandem Meetings; February 2018. Salt Lake City, UT. [abstract] Biol Blood Marrow Transplant. 2018 Mar; 24(3 Supplement):S384. doi: 10.1016/j.bbmt.2017.12.473
Poulos C, Curran D, Anastassopoulou A, De Moerlooze L. German travelers' preferences for travel vaccines assessed by a discrete choice experiment. Vaccine. 2018 Feb 8;36(7):969-78.
Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998
Poulos C, Kinter E, van Beek J, Christensen K, Posner J. Preferences of patients with multiple sclerosis for attributes of injectable multiple sclerosis treatments in the United Kingdom and France. Int J Technol Assess Health Care. 2018 Jan;34(4):425-33. doi: 10.1017/S0266462318000491
Patterson BJ, Buck PO, Carrico J, Hicks K, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and post herpetic neuralgia case avoidance in the US for people previously vaccinated against HZ. Poster presented at the American Society Health System Pharmacist (ASHP) Midyear Clinical Meeting and Exhibition; December 5, 2017. Orlando, FL.
Purser M, Mladsi D, Beckman A, Barion F, Forsey J. Expected budget impact of expanded use of VNS Therapy®. Poster presented at the American Epilepsy Society 71st Annual Meeting; December 2, 2017. Washington, DC.
Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A. Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Graham J, Talbird SE, Monsanto H, Perez Bolde-Villareal C, Daniels V, Pillsbury M, Wolfson LJ. Budget impact of a one-dose varicella vaccination program using outputs of a dynamic transmission model: Mexican national perspective. Poster presented at the 17th Annual Congress of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE); November 2017. Cancun, Mexico.
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Patterson BJ, Buck PO, Carrico J, Hicks KA, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Assessment of the potential herpes zoster and post herpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.
Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.
Hauber AB, Obi EN, Price MA, Whalley D, Chang CL. Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure. Curr Med Res Opin. 2017 Sep;33(11):2027-38. doi: 10.1080/03007995.2017.1355782
Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 2017 Aug;45(3):111-7. doi: 10.1080/21548331.2017.1324227
Mansfield C, Bullok KE, Fuhs JV, Kahle-Wrobleski K, Tockhorn-Heidenreich A, Andrews JS, DiBenedetti DB, Matthews BR, Darling JC, Siemers ER, Hauber AB. The patient voice: exploring treatment preferences in participants with mild cognitive concerns to inform regulatory decision-making. Poster presented at the 2017 Alzheimer’s Association International Conference; July 19, 2017. London, United Kingdom.
Clark M, Schwedt TJ, Tepper SJ, Harris N, Martin S, Sapra S, Shah N. Patient satisfaction with prophylactic migraine medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 2017. Boston, MA. [abstract] Headache. 2017 Jun; 57(Suppl S3):133.
Wasserman M, Rejas J, Mendez C, Wilson M, McDade C, Moffatt M, Farkouh R. Estimating clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) Pneumococcal Conjugate Vaccine in Spain. Presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 24, 2017. Madrid, Spain.
Wasserman M, Wilson M, Breton MC, Peloquin F, McDade C, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent Pneumococcal Conjugate Vaccine (PCV13) to a lower-valent (PCV10) vaccine in Canada. Poster presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 23, 2017. Madrid, Spain.
Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.
Curran D, Van Oorschot D, Buck PO, Patterson BJ, Lee BY, Yawn BP, Hicks KA, Carrico J. Cost-effectiveness analysis of Shingrix for vaccinating US adults against herpes zoster. Presented at the ACIP Herpes Zoster Working Group; May 2017. Atlanta, GA.
Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.
Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.
Johnson KD, Jiang Y, Weiss T, Graham J. Herpes zoster vaccine effectiveness and waning of effectiveness. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A326.
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.
Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Wilson M, Sander S, Kuti E, Lucas A. Cost offsets predicted with empagliflozin in patients with type 2 diabetes and established cardiovascular disease. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S46.
Graham J, Johnson K, Jiang Y, Weiss T. Comparing the estimated potential health impact of 2 herpes zoster vaccines in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.
Hutchinson AB, Hicks KA, Yaylali E, Tucker E, Jacobson E, Sansom SL. Cost-effectiveness of HIV screening of heterosexuals in the United States. Poster presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI); February 14, 2017. Seattle, WA.
Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.
Yaylali E, Farnham P, Sansom S, Hicks KA, Honeycutt A, Tucker E. Using the HOPE model for evaluating HIV interventions in the US. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.
Poulos C, Standaert B, Sloesen B, Hauber AB. What motivates mothers to pay for a vaccine against children's diarrhea? Preferences for vaccines against children's diarrheal illness among mothers in Poland and Hungary. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A419.